Top Page
Neuphoria Therapeutics
(NASDAQ:NEUP)
Neuphoria Therapeutics (NEUP) vs. SPDR S&P 500 ETF (SPY)
Neuphoria Therapeutics Business Overview & Revenue Model
Neuphoria Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -6.38M | 23.95M | 0.00 | 0.00 | ― | 0.00 |
| Gross Profit | -7.30M | 22.94M | -992.56K | -671.42K | 0.00 | -1.69M |
| EBITDA | -1.69B | -268.02K | -22.33M | -21.54M | -28.03M | -6.63M |
| Net Income | -756.49M | -565.77K | -23.19M | -21.65M | -22.94M | -8.65M |
Balance Sheet | ||||||
| Total Assets | 27.34M | 28.59B | 27.65M | 19.39M | 44.93M | 40.77M |
| Cash, Cash Equivalents and Short-Term Investments | 13.65M | 14.21B | 12.61M | 8.06M | 23.09M | 21.41M |
| Total Debt | 85.21K | 116.31M | 272.74K | 257.55K | 477.15K | 652.04K |
| Total Liabilities | 14.83M | 9.59B | 10.16M | 4.74M | 5.78M | 5.01M |
| Stockholders Equity | 12.51M | 19.00B | 17.49M | 14.65M | 39.15M | 35.76M |
Cash Flow | ||||||
| Free Cash Flow | 151.43M | 77.23M | -14.68M | -9.85M | -14.97M | -5.67M |
| Operating Cash Flow | 151.43M | 77.23M | -14.68M | -9.85M | -14.97M | -5.66M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 427.68K | -60.26K |
| Financing Cash Flow | 3.06B | 1.53B | 15.11M | 2.60M | 18.57M | 23.71M |
Neuphoria Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $24.07M | 80.46 | 0.27% | ― | 75.19% | ― | |
52 Neutral | $22.58M | -0.17 | -59.91% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $30.23M | -0.43 | -83.28% | ― | ― | 15.35% | |
40 Underperform | $14.75M | -0.55 | -204.04% | ― | -60.89% | 94.49% | |
38 Underperform | $9.50M | -0.14 | -94.79% | ― | ― | 84.44% |
Neuphoria Therapeutics Corporate Events
Neuphoria Therapeutics Inc. announced that Spyridon “Spyros” Papapetropoulos, M.D., who was appointed president and CEO under an employment agreement effective January 5, 2023, will step down as full-time president and CEO effective December 31, 2025, while remaining on the company’s board of directors. Under his employment agreement, he will receive severance equal to his annual base salary, target bonus and medical insurance premiums, paid partly in 2025 and the remainder in installments through 2026, and his participation in most employee benefit programs will end immediately, though his existing stock options will continue to vest and be exercisable under the company’s equity plan. Concurrently, Papapetropoulos has entered into a consulting agreement effective January 1, 2026, under which he will serve as interim CEO for up to twelve months at an hourly consulting rate, limited to roughly 40 hours per month, to support a planned strategic transaction and oversee leadership transition, with the arrangement set to terminate earlier if the company completes a strategic merger, change of control or similar deal.
The most recent analyst rating on (NEUP) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Neuphoria Therapeutics stock, see the NEUP Stock Forecast page.
On December 12, 2025, Neuphoria Therapeutics held its Annual Meeting of Shareholders, during which voting took place on four key proposals related to corporate governance and strategy. The proposals included the election of two Class I directors for a three-year term, the ratification of Wolf & Company P.C. as the company’s auditors for the fiscal year ending June 30, 2026, a non-binding vote on executive compensation, and a decision on the frequency of future advisory votes on executive pay. The results demonstrated shareholder support across all proposals, suggesting an alignment between company management and its shareholders on governance and strategic priorities.
The most recent analyst rating on (NEUP) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Neuphoria Therapeutics stock, see the NEUP Stock Forecast page.
On October 25, 2025, Neuphoria Therapeutics‘ Board of Directors declared a dividend of rights to purchase Series A Preferred Stock for each common stock share, effective October 27, 2025. The company adopted a stockholder rights plan to prevent hostile takeovers, triggered if an entity acquires 15% or more of common stock without board approval. This plan aims to protect stockholder investments and ensure fair participation in strategic reviews, while not hindering potential beneficial acquisition proposals.
The most recent analyst rating on (NEUP) stock is a Hold with a $2.30 price target. To see the full list of analyst forecasts on Neuphoria Therapeutics stock, see the NEUP Stock Forecast page.
On October 20, 2025, Neuphoria Therapeutics announced that its AFFIRM-1 Phase 3 trial for BNC210 in treating social anxiety disorder did not meet its primary or secondary endpoints. As a result, the company will discontinue its SAD program and conduct a strategic review of its operations and portfolio. Neuphoria will focus on potential developments for BNC210 in PTSD and maintain its partnership with Merck, which includes a Phase 2 trial for Alzheimer’s disease. The company reported a cash position of $14.2 million as of June 30, 2025, expected to fund operations through mid-2027.
The most recent analyst rating on (NEUP) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Neuphoria Therapeutics stock, see the NEUP Stock Forecast page.